HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: thx.2005.044578v1 61/1/29    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Palen, J Articles by Veenstra, D L Search for Related Content PubMed PubMed Citation Articles by van der Palen, J Articles by Veenstra, D L

Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease

¹ Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, The Netherlands
² Department of Pharmacy, University of Washington, Seattle, USA

Correspondence to:
Correspondence to:
Dr J van der Palen
Medisch Spectrum Twente, Concernstaf, Department of Epidemiology, P O Box 50000, 7500 KA Enschede, The Netherlands; vdpalen{at}euronet.nl

Background: The evidence for the effectiveness and safety of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) is inconclusive. This study determined the cost effectiveness of withdrawing fluticasone propionate (FP) in outpatients with COPD.

Methods: The cost effectiveness analysis was based on a randomised, placebo controlled FP withdrawal study. After a 4 month run in period on FP, patients were randomly assigned to continue FP 500 µg twice daily or to receive placebo for 6 months. A decision analytical model evaluated the 6 month incremental cost effectiveness of the ICS versus ICS withdrawal strategy. One way sensitivity analyses and a Monte Carlo simulation were performed to evaluate the robustness of the findings.

Results: The average patient with COPD in the FP group generated 511 in direct medical costs, including 238 for FP. The cost of the placebo strategy was 456. The higher direct drug cost of 212 per patient for the FP strategy during the 6 month follow up period compared with the placebo group was partially offset by a lower exacerbation and hospital admission cost of 157. The 6 month incremental cost effectiveness of the FP strategy compared with placebo was 110 per exacerbation prevented and 1286 per hospital admission prevented.

Conclusions: Over a 6 month period, withdrawing FP in a pre-selected trial population of COPD patients led to absolute cost savings but with a higher rate of exacerbations and hospital admissions.

Abbreviations: COPD, chronic obstructive pulmonary disease; FP, fluticasone propionate; ICS, inhaled corticosteroids

Keywords: cost effectiveness; chronic obstructive pulmonary disease; steroid withdrawal

This article has been cited by other articles:

				P. P. Walker, P. Mitchell, F. Diamantea, C. J. Warburton, and L. Davies Effect of primary-care spirometry on the diagnosis and management of COPD Eur. Respir. J., November 1, 2006; 28(5): 945 - 952. [Abstract] [Full Text] [PDF]